Peptides for autoimmune disease fall into two very different groups. A few are FDA-approved and backed by large trials: icotrokinra (Icotyde), an oral peptide approved in March 2026 for moderate-to-severe plaque psoriasis, zilucoplan (Zilbrysq) for generalized myasthenia gravis, and glatiramer acetate (Copaxone) for relapsing multiple sclerosis.[1][4][6] The peptides sold online for autoimmunity, such as thymosin alpha-1, KPV and BPC-157, have no proof they help people with autoimmune disease; their evidence comes from animals, lab dishes or small, flawed studies.[7][10][11]
This guide grades each by evidence, explains why “immune-boosting” products are a poor fit for autoimmune disease, and lists questions for your specialist. For related compounds, see the longevity and immune peptides hub.
Peptides for autoimmune disease: evidence at a glance
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Icotrokinra (Icotyde) | FDA-approved for this use | 65% clear or almost clear skin vs 8% on placebo at 16 weeks[2] | Approved 2026, plaque psoriasis, age 12+ and 40 kg+[1] | — |
| Zilucoplan (Zilbrysq) | FDA-approved for this use | Larger drop in daily-living symptom scores than placebo[5] | Approved for AChR antibody-positive generalized myasthenia gravis[4] | — |
| Glatiramer acetate (Copaxone) | FDA-approved for this use | Long-used disease-modifying therapy | Approved for relapsing MS[6] | — |
| Thymosin alpha-1 | No evidence, marketing only | Lower blood levels in autoimmune patients; no treatment trials[8] | Not approved; labels abroad urge case-by-case caution[7] | Thymosin alpha-1 |
| BPC-157 | Animal or lab only | One 53-person colitis enema trial, no clear benefit[11] | Not approved | BPC-157 |
| KPV | Animal or lab only | Reduced colitis in mice; no human data[9][10] | Not approved | KPV |
| VIP | Animal or lab only | Prevented arthritis in mice[13] | Not approved for this use | VIP |
| LL-37 | No evidence, marketing only | A T-cell target in two-thirds of people with psoriasis[14] | Not approved | LL-37 |
“Best” here means best supported by evidence, which puts the approved drugs first.
The approved peptide drugs
Icotrokinra for psoriasis
Icotrokinra is a peptide that blocks the interleukin-23 receptor, a key switch in psoriasis inflammation. Other drugs that target this pathway are injected antibodies; icotrokinra is a once-daily pill.[1] In the ICONIC-LEAD phase 3 trial, 684 adults and adolescents with moderate-to-severe plaque psoriasis received icotrokinra 200 mg or placebo. At 16 weeks, 65% on icotrokinra had clear or almost-clear skin versus 8% on placebo, and 50% versus 4% reached a 90% improvement in their psoriasis score. Adverse events were equally common in both groups, mostly colds and upper respiratory infections.[2]
FDA approved it on March 17, 2026, for adults and children 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.[1] It is also being tested in ulcerative colitis: in a 252-person phase 2b trial, clinical response at 12 weeks was 55% to 63% across doses versus 27% on placebo.[3] That use is not approved.
Zilucoplan for myasthenia gravis
Zilucoplan is a small ring-shaped peptide injected under the skin once a day. It blocks complement protein C5, part of the immune attack on nerve-muscle junctions in myasthenia gravis.[4] In the RAISE trial of 174 patients, it improved daily-living symptom scores by 4.39 points versus 2.30 with placebo over 12 weeks.[5] Its label carries a boxed warning for serious meningococcal infections, and patients generally need meningococcal vaccines at least two weeks before the first dose.[4]
Glatiramer acetate for multiple sclerosis
Glatiramer acetate is a mix of synthetic peptides made from four amino acids. It is approved for relapsing forms of multiple sclerosis in adults and is thought to work by modifying immune processes.[6] Its label now carries a boxed warning about rare, life-threatening anaphylaxis, which can happen even years into treatment.[6]
The unproven peptides
Thymosin alpha-1
Thymosin alpha-1 is sold online for “autoimmunity,” but that pitch rests mainly on the idea of immune balancing. A 2016 study found people with psoriatic arthritis, rheumatoid arthritis and lupus had lower blood levels than healthy donors, which shows a difference, not that supplementing helps.[8] When FDA reviewed it, autoimmunity was among the nominated uses, but FDA did not evaluate it as a specific condition, and it noted that labels abroad say use in autoimmune disease must be evaluated case by case.[7] Our thymosin alpha-1 vs LL-37 guide covers its trials in infections, which have been mostly negative.
BPC-157
BPC-157 is promoted for inflammatory bowel disease. FDA reviewed it for ulcerative colitis in 2026 and found one human trial, reported only as a 2005 meeting abstract: 53 people received a BPC-157 enema or placebo for two weeks. Disease scores fell 3.2 points with BPC-157 and 1.6 with placebo, and the difference was not statistically clear. FDA called the data inadequate and found no studies of oral or injected BPC-157 in colitis.[11] See our BPC-157 clinical trials review for the rest of its human record.
KPV
KPV is a three-amino-acid fragment of the hormone alpha-MSH. Given in drinking water, it reduced chemically induced colitis in mice.[9] FDA found no clinical studies or human exposure data for KPV by any route.[10] In July 2026, FDA advisers voted 8 to 6 to recommend adding KPV to the compounding list, but FDA had not acted on that advice, and a vote is not evidence of effectiveness.[12]
VIP and LL-37
VIP prevented joint swelling and destruction in a mouse model of rheumatoid arthritis in 2001, but it has not become an arthritis treatment in people.[13] LL-37 is a cautionary example: in psoriasis it acts as an autoantigen, and about two-thirds of patients with moderate-to-severe disease have T cells that target it.[14]
Why “immune-boosting” is the wrong frame
Autoimmune disease happens when the immune system attacks the body’s own tissues. The approved peptides all work by blocking a specific part of that attack, not by stimulating immunity. Products marketed to “boost” immunity point in the opposite direction, which is why labels for thymosin alpha-1 abroad urge caution in autoimmune disease.[7]
Promising peptides also fail. Larazotide, an oral peptide designed to tighten the gut lining in celiac disease, an autoimmune condition, reached phase 3, but in 2022 its developer stopped the trial after an interim analysis showed too many more patients would be needed to detect a meaningful effect.[15]
Questions for your specialist
- Is my disease controlled on current treatment, and what are the risks if it flares?
- Would an approved targeted therapy, including an oral option, suit me?
- Could a peptide sold online interact with my immunosuppressant or biologic?
- If I try something new, how will we monitor for a flare?
The bottom line
The best peptides for autoimmune disease are the approved ones, each for a specific condition: icotrokinra for psoriasis, zilucoplan for myasthenia gravis and glatiramer acetate for multiple sclerosis. The peptides sold online for autoimmunity have not been shown to help people, and some could interfere with immune control. Related reading: VIP and mold illness and our guide to animal versus human peptide studies.
This is general information, not medical advice.
